Article
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial.
Thrombosis and haemostasis - 4 Jul 2016
Carreras Edward T, Hochholzer Willibald, Frelinger Andrew L, Nordio Francesco, O'Donoghue Michelle L, Wiviott Stephen D, Angiolillo Dominick J, Michelson Alan D, Sabatine Marc S, Mega Jessica L
Abstract excerpt
Both diabetes mellitus (DM) and carriage of the CYP2C19*2 allele are associated with a reduced response to clopidogrel. The relative contributions of these factors and whether higher clopidogrel doses can overcome both factors remain unknown. The objective of this study was to test the ability of clopidogrel doses up to 300 mg daily to decrease platelet reactivity in patients with DM and/or CYP2C19*2....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.